Brief: BioCryst Pharmaceuticals Q2 EPS USD -0.4
03/08/2023 12:01
Aug 03 (Reuters) - BioCryst Pharmaceuticals Q2 net income USD -75.326 million. * Q2 operating income USD -20.703 million * Q2 pretax profit USD -74.586 million * Q2 operating expenses USD 103.194 million * Q2 product sales USD 82.491 million vs. IBES estimate USD 81 million
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026